KLK3 and prostate cancer: Core fucosylated prostate-specific antigen (PSA) may be a diagnostic biomarker for differentiating prostate cancer from other prostate diseases, such as BPH 55, and both serum and urine tests for core fucosylated PSA are feasible options 56.